Skip to content

Study · Randomized controlled trial · n = 2,461 · 2024

4 results

Tirzepatide reduces the predicted risk of atherosclerotic cardiovascular disease and improves cardiometabolic risk factors in adults with obesity or overweight: SURMOUNT-1 post hoc analysis.

Hankosky ER, Wang H, Neff LM, Kan H, Wang F, Ahmad NN, Griffin R, Stefanski A, Garvey WT

Diabetes, obesity & metabolism6 Nov 2023Cited by 73 (Europe PMC)

PMID37932236 (opens in a new tab)DOI10.1111/dom.15318 (opens in a new tab)PepBankPUB-37932236
Publisher pagePubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: CC BY-NC. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

  1. 01HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight without diabetes or prior ASCVD, predicted 10-year ASCVD risk changed by -23.5% to -16.4% with tirzepatide versus 12.7% with placebo at week 72.

    In plain wordsIn adults with obesity or overweight without diabetes, predicted heart disease risk fell more with tirzepatide than with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRelative change in predicted 10-year ASCVD risk at week 72
    Study

    n = 2,461

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    5/10/15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Relative change in risk from baseline to week 72 was greater for tirzepatide (-23.5% to -16.4%) than placebo (12.7%; P < 0.001).
    3 context sentences
    Summary · context
    In participants without a history of ASCVD (N = 2461), the baseline median risk score was low and did not differ across groups (1.5%-1.6%).
    Summary · context
    SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m2 and at least one weight-related complication, excluding diabetes.
    Summary · context
    Participants were randomly assigned to tirzepatide (5/10/15 mg) or placebo.
  2. 02HumanRandomized controlled trialEfficacy outcome

    In adults with obesity or overweight without diabetes, tirzepatide-treated groups showed reductions in cardiometabolic variables over 72 weeks.

    In plain wordsIn adults with obesity or overweight without diabetes, heart and metabolic risk measures fell over 72 weeks with tirzepatide.

    Peptide
    Tirzepatide
    Outcome
    DecreaseCardiometabolic variables over 72 weeks
    Study

    n: not reported in source

    Outcome group
    Cardiometabolic risk factors · Metabolic and weight
    Studied dose
    5/10/15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Tirzepatide-treated groups demonstrated reductions in cardiometabolic variables over 72 weeks.
    2 context sentences
    Summary · context
    SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m2 and at least one weight-related complication, excluding diabetes.
    Summary · context
    Participants were randomly assigned to tirzepatide (5/10/15 mg) or placebo.
  3. 03HumanRandomized controlled trialEfficacy outcome

    In participants with intermediate-to-high baseline ASCVD risk, tirzepatide produced a significantly greater relative change in predicted risk than placebo.

    In plain wordsIn people with intermediate-to-high starting heart disease risk, predicted risk fell more with tirzepatide than with placebo.

    Peptide
    Tirzepatide
    Outcome
    DecreaseRelative change in predicted ASCVD risk, intermediate-to-high baseline risk
    Study

    n: not reported in source

    Comparator
    Placebo
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    5/10/15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Relative change among participants with intermediate-to-high baseline risk was significantly greater for tirzepatide (P < 0.05).
    2 context sentences
    Summary · context
    SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m2 and at least one weight-related complication, excluding diabetes.
    Summary · context
    Participants were randomly assigned to tirzepatide (5/10/15 mg) or placebo.
  4. 04HumanRandomized controlled trialEfficacy outcome

    Intermediate-to-high-risk participants had a similar relative change but a greater absolute risk reduction than the overall population.

    In plain wordsIn people with higher starting risk, tirzepatide gave a similar relative drop in predicted heart disease risk but a larger absolute drop than in everyone.

    Peptide
    Tirzepatide
    Outcome
    DecreaseAbsolute reduction in predicted ASCVD risk, intermediate-to-high-risk participants
    Study

    n: not reported in source

    Comparator
    Overall population
    Outcome group
    Cardiovascular events · Cardiovascular
    Studied dose
    5/10/15 mg · 72 weeksAs given in this study (human).

    Source sentences

    Summary
    Intermediate-to-high-risk participants demonstrated similar relative change but greater absolute risk reduction compared to the overall population.
    2 context sentences
    Summary · context
    SURMOUNT-1, a phase 3 trial, evaluated the efficacy and safety of tirzepatide in adults with body mass index ≥30 or ≥27 kg/m2 and at least one weight-related complication, excluding diabetes.
    Summary · context
    Participants were randomly assigned to tirzepatide (5/10/15 mg) or placebo.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Registered trials1

Trials this study reports on, or that list this study as a reference. Registry data from ClinicalTrials.gov.

1 trial · 1 not yet recruiting · source ClinicalTrials.gov (opens in a new tab)

Not yet recruitingPhase 3NCT07738276

Evaluation of the Efficacy and Safety of Tirzepatide, a Dual GLP-1/GIP Agonist, on Functional Capacity in Reduced Ejection Fraction Heart Failure Patients With Obesity

Shahid Beheshti University of Medical Sciencesn = 60est. 18 Jul 2026 to est. 22 Dec 2027

Heart Failure and Reduced Ejection Fraction · Obesity & Overweight · Tirzepatide

Trial pageClinicalTrials.govUpdated 3 Aug 2026

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    12 Oct 2026, 12:58 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:07 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.